You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Clorox expects input cost inflation of about $240 million, $40 million above its beginning-of-year forecast, and plans productivity, RGM and targeted pricing to support second-half margin recovery. Fabian Garcia was appointed CEO.
The Clorox Company reported net sales of 1,905, up 33%, and diluted EPS of 1.39, up 114%, in the quarter ended September 30, 2026; gross margin declined to 40.4% as higher commodity, manufacturing and logistics costs offset volume and savings.
Clorox reported first-quarter fiscal year 2027 net sales up 33% to $1.91 billion and adjusted EPS up 82% to $1.55. It maintained adjusted EPS guidance of $5.70 to $6.00 but expects results closer to the low end amid higher input costs.
The Clorox Company appointed Fabian Garcia as CEO and board member effective January 5, 2027. Linda Rendle will step down and serve as senior advisor through April 2, 2027, while Matthew J. Shattock becomes Independent Chair.
Clorox appointed Fabian Garcia as CEO and Board member effective January 5, 2027; Linda Rendle will step down as CEO, chair and director, then advise through April 2, 2027, while Matthew J. Shattock becomes Independent Chair.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
TL;DR. Clorox delivered FY26 results in line with expectations, with full-year organic sales down 8% and adjusted EPS down 28%, as lapping of ERP-related shipments pressured comparisons. For FY27, the company guided to net sales up 13%-14% and adjusted EPS of $5.70-$6.00, including a benefit from lapping the prior-year ERP inventory drawdown, but expects ~$200M+ in inflation driving gross margin to only ~42%.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted after tax profit attributable to Clorox non-GAAP | $775M | FY26 filing | — |
| Adjusted free cash flow as a percentage of net sales non-GAAP | 13.1% | fiscal year 2026 filing | — |
| Average capital employed non-GAAP | $4.2B | FY26 filing | — |
| Bags and wraps (as a percentage of consolidated net sales) | 15% | fiscal year ended June 30, 2026 filing | — |
| Capital charge non-GAAP | $378M | FY26 filing | — |
| Capital expenditures as a percentage of net sales | 3.1% | fiscal year 2026 filing | — |
| Cat litter products (as a percentage of consolidated net sales) | 10% | fiscal year ended June 30, 2026 filing | — |
| Cleaning products (as a percentage of consolidated net sales) | 44% | fiscal year ended June 30, 2026 filing | — |
| Dividends paid to shareholders | 602M | fiscal year 2026 filing | — |
| Economic profit non-GAAP | $397M | fiscal year 2026 filing | — |
GAAP → non-GAAP reconciliationGAAP Earnings before income taxes 791M
+117M Certain U.S. GAAP items
+130M Interest expense
-249M Income taxes on earnings before income taxes, certain U.S. GAAP items and interest expense
-14M After tax profit attributable to noncontrolling interests
-378M Capital charge
= Economic profit 397M
|
|||
| Employees worldwide | 9,200 | fiscal year 2026 filing | — |
| Food products (as a percentage of consolidated net sales) | 11% | fiscal year ended June 30, 2026 filing | — |
| Number of countries or territories of operations | 25 | fiscal year 2026 filing | — |
| Number of markets where products are sold | 95 | fiscal year 2026 filing | — |
| Organic sales growth (non-GAAP) non-GAAP | -8% | Year Ended June 30, 2026 filing | — |
| Organic sales growth / (decrease) non-GAAP | -8% | fiscal year 2026 filing | — |
| Percent of net sales attributable to U.S. markets | 84% | fiscal year 2026 filing | — |
| Recordable incident rate (RIR) | 0.63 | fiscal year 2026 filing | — |
| Share of sales from brands holding No. 1 or No. 2 market share positions | 80% | fiscal year 2026 filing | — |
| Total incremental transformational investment | 580M | fiscal year 2026 filing | — |
| U.S. retail advertising investments as a percentage of net sales | 12% | fiscal year 2026 filing | — |
| Adjusted EBIT margin non-GAAP | 15.3% | FY 2026 (twelve months ended 6/30/26) | — |
| Adjusted EBIT – non-GAAP non-GAAP | $1.03B | FY 2026 (twelve months ended 6/30/26) | — |
| Adjusted EPS non-GAAP | $5.53 | fiscal year 2026 | — |
| Adjusted free cash flow – non-GAAP non-GAAP | $881M | Fiscal year 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net cash provided by operations – GAAP $612M
-$207M Capital expenditures
+$476M Venture agreement termination payment
= Adjusted Free Cash Flow $881M
|
|||
| Free cash flow as a percentage of net sales – non-GAAP non-GAAP | 13.1% | Fiscal year 2026 | — |
| Organic sales non-GAAP | 8% | fiscal year 2026 | — |
| Organic sales growth / (decrease) (non-GAAP) non-GAAP | -13% | Three months ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CLX
this stock
Clorox Co
|
$13.26B | +8.6% | +2.5% | 19.7 | 8.9% |
|
PG
PROCTER & GAMBLE Co
|
$393.56B | +18.5% | +3.3% | 25.6 | 1.0% |
|
UL
Unilever PLC
|
$142.57B | +1.2% | — | — | 0.3% |
|
CL
Colgate Palmolive Co
|
$79.23B | +26.1% | +1.7% | 38.9 | 2.3% |
|
RBGLY
Reckitt Benckiser Group PLC
|
$47.99B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
The Clorox Company reported net sales of 1,905, up 33%, and diluted EPS of 1.39, up 114%, in the quarter ended September 30, 2026; gross margin declined to 40.4% as higher commodity, manufacturing and logistics costs offset volume and savings.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CLX | +9.5% | +25.7% | +13.8% | +24.4% | +8.6% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | +6.9% | +26.9% | +13.3% | +24.6% | -2.1% |
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
